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A  B  S  T R  A  C  T  We have studied the effects of local anesthetics QX 572, which is 
permanently  charged,  and  benzocaine,  which  is  neutral,  on  batrachotoxin- 
activated sodium channels in mouse neuroblastoma N 18 cells. The dose-response 
curves for each drug suggest that QX 572 and benzocaine each act on a single 
class of binding sites. The dissociation constants are 3.15 ￿  10  -s M for QX 572 
and 2.64 ￿  10  -4 M for benzocaine. Equilibrium and kinetic experiments indicate 
that both drugs are competitive inhibitors of batrachotoxin. When benzocaine 
and QX 572 are present with batrachotoxin,  they are much more effective at 
inhibiting Na  § flux than would be predicted by a one-site model. Our results 
indicate  that  QX  572  and  benzocaine  bind  to separate  sites,  each  of which 
interacts competitively with batrachotoxin. 
INTRODUCTION 
Local anesthetics have been shown to depress the excitability of nerve fibers 
by blocking Na § channels  (Taylor,  1959; Hille,  1966; Narahashi et al.,  1968). 
The  extent  of inhibition  of sodium  current  is  enhanced  in  some  cases  by 
repetitive  depolarizing  pulses  and  is  reduced  in  some  cases  by  prolonged 
hyperpolarization  (Strichartz,  1973;  Courtney,  1975;  Khodorov et al.,  1976; 
HiUe,  1977 b;  Cahalan,  1978;  Lipicky et  al.,  1978;  Yeh,  1979).  These drugs 
alter the gating processes of Na  + current.  Benzocaine and a  few tertiary and 
quarternary amine local anesthetics produce a negative voltage shift of sodium 
inactivation  curves  (Courtney,  1975;  Hille,  1977  b;  Schwartz  et  al.,  1977). 
When the sodium inactivation is eliminated with pronase, the voltage-depen- 
dent block of many of these drugs is partially or totally abolished  (Cahalan, 
1978; Yeh,  1979). QX 314, QX 572, and benzocaine have also been shown to 
immobilize the gating charge of sodium channels in squid axon and frog node 
(Cahalan and Almers,  1979; Khodorov et al.,  1979; Gusel'nikova et al.,  1979). 
These observations led to the suggestion  that  local anesthetics  interact  with 
the  inactivation  gating  mechanism  of the  Na  +  channels  (Courtney,  1975; 
Hille,  1977 b; Yeh,  1979; Cahalan  and Almers,  1979). 
Because  both  permanently  charged  and  permanently  uncharged  local 
anesthetics  shift  the  inactivation  curve  in  a  similar  manner,  Hille  (1977  b) 
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proposed that both types of local anesthetics bind to a single receptor site. In 
this model, uncharged or lipid-soluble drugs get to the receptor site through 
the hydrophobic region of the membrane; charged or hydrophilic drugs gain 
access to the receptor via the lumen of the channel. The apparent differences 
in the action of charged and uncharged local anesthetics would then be caused 
by their different rates of action. 
Khodorov  et  al.  (1976) suggested  that  there  might  be  more  than  one 
receptor for  local  anesthetics.  Mrose  and  Ritchie  (1978) tested  whether a 
single-receptor-site model could explain the relative effectiveness of mixtures 
of benzocaine and  lidocaine compared with  the effectiveness of each drug 
alone. They first determined concentrations of each of the two drugs that were 
equipotent in reducing the compound action potential in frog sciatic nerves to 
a standard amplitude. Then they applied a mixture of half of the equipotent 
concentration of benzocaine  and  half of the  equipotent  concentration of 
lidocaine. If both drugs act at the same receptor site, and only at that one site, 
then the mixture should reduce the action potential to the same standard level 
as  either equipotent  solution  alone.  When  Mrose and  Ritchie applied  the 
mixture, however, they observed a  reduction in the amplitude of the action 
potential  that  was significantly larger than  the reduction caused by either 
equipotent solution alone. This result contradicts the hypothesis of a  single 
receptor site. It does not rule out the possibility that lidocaine and benzocaine 
act on the same site, and that, in addition, one of the drugs also acts at another 
site. Indeed, Mrose and Ritchie suggest this as a plausible explanation. 
To determine whether charged and uncharged local anesthetics do, in fact, 
act at the same site,  we have studied the interaction of benzocaine and Q X 
572,  a  lidocaine derivative, on batrachotoxin-activated sodium channels in 
N18 neuroblastoma cells.  We chose permanently charged QX 572  and per- 
manently neutral benzocaine for our studies to avoid changes in the degree of 
ionization of these amine local anesthetics during the experiments, and thus 
simplified the interpretation of our results. Another reason for choosing QX 
572 is that it is relatively lipid soluble, and, therefore, can cross the membrane 
in a reasonable time. This is important because charged lidocaine derivatives 
have been shown to act from the internal membrane surface (Frazier et al., 
1970; Hille, 1977 a). 
The Na  § permeability for different concentrations of the local anesthetics 
was determined by measuring ~Na  + uptake through batrachotoxin-activated 
channels.  Batrachotoxin  (BTX),  a  toxin produced by the Colombian frog, 
Phyllobates aurotaenia, has  been  shown  to  act  specifically on  Na  §  channels 
(Albuquerque et al.,  1971; Narahashi et al.,  1971; Catterall, 1975; Khodorov 
et  al.,  1975; Khodorov,  1978) and cause the channels to open persistantly. 
The interaction of externally applied BTX and QX 572 has previously been 
studied  in  squid  axon  by Albuquerque et  al.  (1973) and  in  frog node by 
Khodorov (1978). In the squid experiments, no interaction between BTX and 
QX 572 was found, whereas in the frog node, there was competitive inhibition. 
Because QX 572 probably acts only from the internal membrane surface, but 
was  applied  externally,  the  different  results  may  be  related  to  different 
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The increase in steady-state 22Na+ influx in the presence of BTX provides 
an  accurate  measure  of Na  +  permeability  through  the  sodium  channels 
(Catterall,  1977).  By using a  large number of tissue culture dishes with BTX 
and various concentrations of one or both local anesthetics, we obtained a set 
of dose-response curves for each drug alone and for the two drugs together. 
These curves provide a detailed test as to whether charged or uncharged local 
anesthetics act at  the same site.  Preliminary results of this work have been 
presented (Huang and Ehrenstein, 1980). 
MATERIALS  AND  METHODS 
Material 
The media and chemicals used were obtained from the following sources: Dulbecco- 
Vogt modification of Eagle's minimal essential  medium (DMEM)  and Dulbecco's 
phosphate-buffered saline from the media unit of the National Institutes of Health, 
Bethesda, Md.; Fetal calf serum was from Grand Island Biological Co., Grand Island, 
N.  Y.;  recrystallized trypsin from Worthington Biochemical Co., Freehold, N. J.; 
Ouabain  from  Sigma Chemical Corp.,  St.  Louis, Mo.;  Benzocaine from  Aldrich 
Chemical Co.,  Milwaukee, Wis.;  22NaCI from Amersham/Searle Corp.,  Arlington 
Heights, Ill; [1,2,3-aH]Leucine from New England Nuclear, Boston, Mass. Batracho- 
toxin was kindly supplied by Dr. J. Daly, Laboratory of Digestive Diseases, National 
Institute  of Arthritis,  Metabolism  and  Digestive  Diseases, National  Institutes  of 
Health, Bethesda, Md. QX  572  C1 was kindly provided by Dr.  B. Takman, Astra 
Pharmaceutical Product Co., Framingham, Mass. 
Cell Culture 
Cell  lines N18 of mouse neuroblastoma, C1300 were grown as described (Catterall, 
1975; Huang et al.,  1979). [aH]leucine  (0.2 Ci/ml) was added to growth media 1 d 
before use so that the aH in the protein recovered in the experiments could be counted. 
Measurement of Influx Rate 
Cells were first preincubated with drug and/or toxin at 36~  for 60 min in a sodium- 
free medium consisting of 135 mM KCI, 5.5 mM glucose, 0.8 mM MgSO4, and 50 
mM  N-2-hydroxyethylpiperazine-N'-2-ethane sulfonic acid  (HEPES)  (pH  7.4, ad- 
justed with tris(hydroxymethyl)aminomethane  [Tris]) and 1 mg/ml of bovine serum 
albumin. Sixty minutes were  long enough to achieve equilibrium, as we found by 
measurement of sodium uptake as a function of time following addition of drug and 
toxin. The initial rate of  passive ~2Na+ influx was measured for 30 s in uptake medium 
containing the same concentration of toxin and/or drug, 130.0 mM choline chloride, 
5.0 mM NaCI, 5.4 mM KCI, 5.5 mM glucose, 0.8 mM MgSO4, 5.0 mM Ouabain, 50 
mM HEPES  (pH  7.4; adjusted with Tris)  and  1 pCi/ml ~ZNaCI. The dissociation 
constant of activation by BTX is 0.4-0.7 #M (Catterall, 1975 and 1977; Huang et al., 
1979).  1 #M BTX, which corresponds  to 75-90% of the maximum response, was used 
in most of  the experiments. This concentration was chosen because of  the low solubility 
of BTX in water and the limited supply of the toxin. The uptake was terminated by 
washing the cells four times with 3 ml of 0~  wash medium consisting of 135 mM 
choline chloride, 5.4 mM KCI, 1.8 mM CaC12, 0.8 mM MgSO4, and 5.0 mM HEPES 
(adjusted pH to 7.4 with Tris base). 
Cells were then suspended in 0.6 ml of  0.4 N NaOH and transferred to a scintillation 
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(5.53%  [vol/vol],  Research  Products  International  Corp.  [Elk  Grove Village,  Ill.] 
scintillator  fluid,  61.14%  toluene, and  33.3%  Triton  X-100).  The  cell  protein  was 
determined by a modification of the Lowry method (Lowry et al.,  1951). 
RESULTS 
Inhibition of QX 572 and Benzocaine 
The effect of QX 572 or benzocaine on BTX-activated uptake is given in Fig. 
I. QX  572 and benzocaine inhibit 80% of the BTX-dependent Na + uptake at 
about  0.4  and  4  mM,  respectively. The dose-response curve  (Fig.  I)  can  be 
well  fit  by  a  modified  Michaelis-Menten  equation  (modified  to  reflect  the 
inhibitory nature of the drug);  V =  Vmax [I  -  A/(Ki +  A)], where Ki is the 
T  .  100  ~;L  aL 
1 
Z 
.,/,  .........  I  ........  I  ........  1  ........  i  ........  ] 
10-6  10-5  10-4  10-3  10-z 
CONCENTRATION  OF LOCAL ANESTHETICS  (M) 
FIGURE  1.  Inhibition of BTX-dependent Na + uptake by Q X  572 and benzo- 
caine. Cells were preincubated with 1/~M BTX and the indicated concentrations 
of local anesthetics  for 60  rain.  Z2Na+ uptake was  then  measured  for 30  s in 
uptake medium containing the same amount of BTX and local anesthetics as 
the  preincubation  medium.  The solid  line  is  the  best  fit  of the  data  to  the 
modified Michaelis-Menten equation. The error bars represent standard devia- 
tions. The arrows indicate the Ki of QX 572 or benzocaine. 
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apparent  dissociation constant  of the  inhibitor,  A  the concentration of local 
anesthetic,  V,  nax the maximum  uptake in the absence of inhibitor, and  V the 
uptake  measured  at  various  drug  concentrations.  The  data  have  a  Hill 
coefficient of ~1.0.  These results suggest  that  benzocaine and QX  572 each 
act on a  single class of binding sites. The apparent dissociation constants are 
Ki  =  9.0  +  2.0  X  10  -5  M  for QX  572  and  Ki  =  8.0  -4-  1.5  X  10  -4  M  for 
benzocaine. Thus, QX  572 is about nine times more potent in blocking Na + 
channels  than  benzocaine.  These  results  are  in  general  agreement  with  the 
work on frog sciatic nerve (Hille,  1977 b). 
Interaction of QX 572 and Benzocaine with BTX 
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22Na+  uptake  at  various  concentrations  of BTX  in  the  presence  of several 
different concentrations  of QX 572 or benzocaine. The data were plotted on 
double-reciprocal  coordinates  (Fig.  2).  The  experimental  results,  using  an 
iterative least-square procedure,  were fit to the Michaelis-Menten  equation: 
V  ffi  Vn~,  B/(K,  +  B),  where  B  is  BTX  concentration,  K,  the  apparent 
dissociation constant for BTX. As the local anesthetic concentration increases, 
the slope of the corresponding reciprocal plot also increases. K, (reciprocal of 
the abscissa intercept)  increases markedly with increasing drug concentration. 
In contrast, the maximum  level of activation  Vm~ (reciprocal of the ordinate 
intercept) is little affected. Thus, both QX 572 and benzocaine are competitive 
inhibitors  of BTX activation.  A  replot of K, for each reciprocal plot  vs. the 
corresponding drug concentration gives a  straight  line (Fig. 2, inset). The true 
dissociation constants of QX 572 and benzocaine can be calculated from the 
abscissa intercepts of the replots. They are 3.15 _  0.70 X  10 -5 M  for QX 572 
and  2.64  __.  0.40  ￿  10 -4  M  for  benzocaine.  These  results  suggest  that  the 
binding of BTX and  the binding of local anesthetics QX 572 or benzocaine 
are mutually exclusive. 
Interaction between QX 572 and Benzocaine 
Although  QX  572 and  benzocaine are both competitive inhibitors  of BTX, 
this does not necessarily imply that QX 572 and benzocaine act on the same 
site. Competitive inhibition patterns may arise in two ways: (a) the drug binds 
at  the  BTX  site and  then  physically prevents  the  binding  of BTX;  (b)  the 
drug binds to a site separate from the BTX site. The binding of the drug can 
then cause either a  conformational change in the BTX receptor site or steric 
hindrance.  As a  result,  BTX can no longer bind.  In case b, two drugs could 
bind  to  two  separate  sites  and  still  both  be  competitive  with  BTX.  To 
determine  the  mechanism  in  the case of QX  572  and  benzocaine,  we mea- 
sured the inhibition of BTX-activated Na  + uptake by QX 572 in the presence 
of several concentrations of benzocaine or vice versa. If both drugs bind to the 
same site and only to that  site, the apparent  dissociation constant Ki for one 
drug  should  increase with  increasing  concentration  of the  second  drug.  On 
the contrary, as shown in Fig. 3, the presence of benzocaine decreases the Ki 
of QX 572, and the presence of QX 572 decreases the Ki of benzocaine. 
DISCUSSION 
Batrachotoxin causes as much as a  25-fold increase in the initial  rate of Na  + 
uptake in  N18 mouse neuroblastoma cells  (Catterall,  1975).  This  increase is 
completely abolished at low concentration of tetrodotoxin--a specific inhibitor 
of Na + channels (Catterall,  1975). On the other hand, neuroblastoma cell lines 
specifically  lacking  Na  +  channels  (Minna  et  al.,  1971)  do  not  respond  to 
treatment  with  BTX  (Catterall  and  Nirenberg,  1973;  Catterall,  1975  and 
1977).  Khodorov and co-workers (1975 and  1978) studied the action of BTX 
in node of Ranvier and observed that  BTX-modified Na § current  developed 
concurrently  with  the  disappearance  of normal  Na  + current.  This  evidence 
supports the view that  BTX is a  specific activator of Na  + channels  and that 
the increase in the rate of Na uptake reflects the opening of Na § channels.  In 142  THE  JOURNAL  OF  GENERAL  PHYSIOLOGY  ￿9  VOLUME  77  ￿9  1981 
the  discussion  to  follow, we  assume  that  this  specificity of BTX  action  is 
correct. 
Our  equilibrium experiments show that  both  local  anesthetics markedly 
affect the apparent dissociation constant of BTX and have little effect on the 
maximum ion flux at  1 #M BTX  (Fig. 2).  Thus, the binding of QX 572  or 
benzocaine and the binding of BTX are mutually exclusive. 
Our results with QX 572  agree with the finding of Khodorov (1978)  that 
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FIGURE 2.  Double reciprocal  plot describing the interaction of BTX and the 
local anesthetics.  (a) The cells were preincubated with the indicated concentra- 
tions of BTX containing 0 (Q), 0.1 mM (O), 0.2 mM (A), 0.3 mM (A) QX 572 
for 60 min. 22Na+ uptake was then measured. The solid line is the least square 
fit to the equation V =  Vm~x'B/(Ka  +  B), where V is the uptake and  Vmax is 
assumed to be constant. The Ka'S obtained at different QX 572 concentrations 
are replotted as a function of QX 572 concentration (inset). The intercept on the 
abscissa gives the true dissociation constant for QX 572. (b) Same experiment as 
in a with 0 (O), 0.8 mM (C)), 1.2 mM (&), and 1.5 mM (l~) benzocaine. 
BTX antagonizes the blocking action of  this drug. Our results with benzocaine, 
however, do not agree with Khodorov's observation that the blocking action 
of benzocaine is not affected by BTX in frog node (Khodorov, 1978). Although 
the source of this discrepancy is uncertain, a  closer look at Khodorov's data 
does reveal a  small interaction between benzocaine and BTX. When 3 mM 
benzocaine was applied to the frog node, normal Na  + current was reduced HUANC AND  EI'iRENSTEIN QX  572 and Benzocaine Act at Separate Sites  143 
71%,  but  BTX-activated  Na +  current  was  reduced  only  58%  (Khodorov, 
1978).  Thus,  Khodorov's data  is consistent  with benzocaine having  a  small 
effect on  BTX  binding  in  the  frog node.  As we have  shown  in  this  paper, 
benzocaine is a much less potent inhibitor than QX 572. It is possible that the 
concentration  of benzocaine used  in  frog node is either  not high  enough  to 
completely block normal  Na  +  current,  or  is  not  as  effective as  QX  572  in 
displacing BTX. Negulyaev and Nosyreva (1979) have shown that in the frog 
node the apparent  dissociation constant of benzocaine is larger for aconitine- 
activated Na  + channels  than  for normal  Na  + channels.  Aconitine and BTX 
have a  common  binding site  (Catterall,  1977)  and these two alkaloid  toxins 
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way  (Schmidt  and  Schmidt,  1974;  Mozhayeva  et  al.,  1977).  Thus,  it  is 
consistent that  benzocaine interacts competitively with BTX as well as with 
aconitine. 
We have shown  in  Fig.  1 that  QX  572 and  benzocaine each reduces  the 
BTX-activated  Na  + flux.  Although  the experimental  data of Fig.  I  are not 
sufficiently accurate to rule out the possibility that each local anesthetic binds 
to multiple sites, a better fit is obtained under the assumption that each local 
anesthetic binds to a  single site. 
We have shown in Fig.  3 that  the apparent  dissociation constant of either 
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FIGURE  3.  (a)  Effect  of benzocaine on  Q￿  572  inhibition of BTX-activated 
Na +  uptake.  Cells were  incubated  in  preincubation  media  containing  1 #m 
BTX, the indicated concentration of QX  572, and 0  (O), 3  ￿  10 -4 M  (C)), and 
7 X  10 -4 M  (&) benzocaine for 60 rain. Na  + uptake was measured in the assay 
medium for 30 s. The solid line is the least squares fit to the modified Michaelis- 
Menten  equation.  The arrows  indicate the Ki of QX  572  for each  benzocaine 
concentration. (b) Effect of QX 572 on benzocaine inhibition of BTX-activated 
Na  + uptake. The experimentalsproeedure is the same as in a. QX  572  concen- 
trations were 0  (O), 6.25  x  10-  M  (O), and  1.46 X  10 -4 M  (&). HUANG AND ERRENSTEIN  QX 572 and Benzocame Act at Separate Sites  145 
local  anesthetic  is  added.  This  agrees  with  the  observation  of Mrose  and 
Ritchie  (1978)  that  a  mixture  of charged  and  uncharged  local anesthetics  is 
more  effective in  reducing  the  amplitude  of the  action  potential  than  is  a 
single local anesthetic. 
Next, we would like to consider possible models that would account for the 
increased  effectiveness of mixtures  of local  anesthetics  (Fig.  3).  The  specific 
models considered are the following: 
(a)  One-Site Model 
The binding of the charged  local anesthetic,  the uncharged  local anesthetic, 
and  BTX  are all  mutually  exclusive.  In  the simplest  case,  there  is only one 
binding site for all these molecules, but there may be more than one binding 
site if there are allosteric interactions.  The only requirement  of this model is 
the mutual exclusivity of binding of the three molecules. 
(b)  Two-Separate-Site Model 
Each channel  has two binding sites for local anesthetics:  one site for charged 
local anesthetics and a  separate site for uncharged  local anesthetics.  The two 
local anesthetics can simultaneously bind to the same channel.  The binding 
of either  of these  drugs  to  its  site  and  the  binding  of BTX  are  mutually 
exclusive. 
(c) Intermediate Model 
Each channel  has two binding sites for local anesthetics:  one site  (site A)  for 
either charged or uncharged  local anesthetics,  and  the other site  (site B)  for 
uncharged local anesthetics only. Thus, each channel has one site for charged 
local anesthetics but two sites for uncharged local anesthetics. The affinities of 
the two sites for the uncharged  drug are assumed to be equal.  Charged  and 
uncharged local anesthetics compete for site A. The occupancy of site A and/ 
or  site  B  prevents  the  binding  of BTX.  This  model  is  very similar  to  that 
proposed by Mrose and Ritchie (1978). 
If we generalize model c by allowing the uncharged local anesthetic to have 
different affinities for its two sites, then models a, b, and c can all be considered 
special cases of this generalized model. The one-site model corresponds to the 
case in which the affinity of site B  for the uncharged  local anesthetic  is very 
low. The two-separate-site model corresponds to the case in which the affinity 
of site  A  for  the  uncharged  local  anesthetic  is  very low.  The  intermediate 
model corresponds to the case in which the affinities of site A  and site B  for 
the uncharged  local anesthetic are equal.  In all cases, we assume that  site A 
and site B are independent. 
Explicit  dose-response  relations  for  the  three  models  with  and  without 
addition  of a  second drug are derived in the Appendix.  For the one-site and 
two-separate-site models, the apparent  dissociation constants are tabulated in 
Table I. Both of these models give the same apparent dissociation constant in 
one-drug  experiments  but  different  apparent  dissociation  constants  in  two- 
drug  experiments.  Predictions  of the  intermediate  model  depend  on  which 
drug is being varied and will be discussed later. Interestingly, each of the three 146  THE JOURNAL OF GENERAL PHYSIOLOGY ￿9 VOLUME 77 ￿9 1981 
models  gives  a  very  different  prediction  concerning  the  change  in  dose- 
response curve caused by the addition of a second drug. 
As shown in Table I, the one-site model predicts that the addition of a fixed 
concentration of one local anesthetic would increase the apparent dissociation 
constant  for  the  dose-response  curve  of  the  other  local  anesthetic.  This 
corresponds to a shift of the dose-response curve to the right. By contrast, the 
two-separate-site  model  predicts  that  the  addition  of one  local  anesthetic 
would decrease the apparent dissociation constant of the other local anesthetic. 
This corresponds to a shift of the dose-response curve to the left. 
Before we describe the predictions of the intermediate model, let us consider 
the underlying reasons for the qualitative difference between the predictions 
of the one-site model and the predictions of the two-separate-site model. Let 
Q  represent the drug whose concentration is  varied and B  the drug that  is 
present at a fixed concentration. For the one-site model, at low dose of Q, the 
drug B effects a significant reduction in the number of open channels. As the 
concentration of Q  increases, the effectiveness of drug B decreases, until at a 
very high concentration of Q  the presence of drug B has virtually no effect. 
TABLE  I 
THEORETICAL APPARENT DISSOCIATION CONSTANTS 
K~ 
l Drug  KQ (l + [BTXI'I 
2-Drug, 1-Site  KQ (1 +~  +-~B]  ) 
+ [BTXl + IBI \ 
2-Drug, 2-Separate-Site  KQ 
l + !B]  /  r~B 
Thus, for the one-site model, drug B lowers the dose-response curve consider- 
ably at the left end and very little at the right end. As a result, the normalized 
dose-response curve shifts to the right, and Ki increases. As shown quantita- 
tively in the Appendix and Table I, the addition of drug B increases Ki by an 
amount 
\KB/ 
(where KQ and KB are the true dissociation constants for drug Q  and drug B). 
In the case of the two-separate-site model, there are two effects that must be 
considered.  First,  the presence of a  fixed concentration of drug B  tends  to 
increase Ki in  the two-separate-site model as  it  does in  the one-site model. 
However,  there  is  an  additional  effect in  the  two-separate-site  model  that 
tends to decrease Ki. This additional effect results from the availability of two 
noncompetitive sites, allowing two drug molecules to bind at the same channel 
simultaneously.  The  second  binding  does  not  affect  the  flux  through  the HUANC AND EHRENSTEIN  QX 572 and Benzocaine Act at Separate Sites  147 
channel,  because  the  channel  is  assumed  to  be  completely closed  by  the 
binding of the first drug. However, the second binding decreases the proba- 
bility that the closed channel will open, because opening requires the dissocia- 
tion  of both  drug  molecules from  their  sites.  This  drives  the  equilibrium 
toward the closed state. The importance of this additional effect increases as 
the concentration of the variable drug Q  increases, because that increases the 
number of channels with two drugs bound. Thus, the additional effect lowers 
the dose-response curve considerably at the right end and very little at the left 
end. As a result, in experiments with two drugs, the dose-reponse curve for the 
two-separate-site model is shifted to the left relative to the dose-response curve 
for the one-site model. In fact, the additional effect that occurs only in  the 
two-separate-site model is the larger effect. Therefore, in the two-separate-site 
model, the addition of drug B results in a decrease in Ki. As shown quantita- 
tively in the Appendix and Table I, the amount of this decrease is 
\ K. K.Tx ]/\  K.] 
(where KBTX is the true dissociation constant for BTX). 
Next, let us consider the predictions of the intermediate model. For the two- 
drug experiments, as shown in the Appendix, the dose-response curve has a 
different form, depending on whether the concentration of the charged or the 
uncharged local  anesthetic is  being  varied.  The  dose-response curve has  a 
Michaelis-Menten form when the charged local anesthetic is varied, but does 
not  have this  form when the uncharged local  anesthetic is  varied.  For the 
former case, the apparent dissociation constant is shown in the Appendix (Eq. 
6A). For the latter case, the apparent dissociation constant was determined by 
numerically calculating the normalized dose-response curve, and then evalu- 
ating the dose where the normalized response equals 0.5.  In each case,  the 
predictions of the intermediate model for one-drug experiments were deter- 
mined by setting the fixed-drug concentration equal to zero. 
A convenient parameter for comparing the predictions of the three models 
with the experiments of Fig. 3 is the ratio of the apparent dissociation constant 
for a one-drug experiment to the apparent dissociation constant after a  fixed 
concentration of the other drug is added. This ratio is a  measure of the shift 
of the dose-response curve when the second drug is added. Ratios less than  1 
correspond to shifts to the right, and ratios greater than 1 correspond to shifts 
to the left. 
Table II compares experimental values of the apparent dissociation constant 
ratio with the predictions of the three models for four different experimental 
conditions. For each condition, the experimental ratios are near 2, correspond- 
ing to substantial  shifts of the dose-response curves to the left. The one-site 
model and the intermediate model predict ratios less than or about equal to 
l, corresponding to shifts of the dose-response curve to the right, or essentially 
no shift. Only the two-separate-site model predicts a ratio near 2, correspond- 
ing to  substantial  shifts of the dose-response curve to  the left, and  in  good 
agreement with experiment. This demonstrates unambiguously that Q X  572 
and benzocaine act at separate sites in the sodium channel. 148  THE  JOURNAL  OF  GENERAL  PHYSIOLOGY,  VOLUME  77"  1981 
Where are these binding sites for the local anesthetics located? Two different 
sites  of action  have  been  proposed  to  account  for  the  reduction  of sodium 
conductance by local anesthetics. First, the local anesthetics may bind directly 
to a specific site on the gating molecules. The binding holds the sodium gates 
in the closed conformation or inactive state and thus decreases Na  + permea- 
bility  (Huang  et  al.,  1978;  Lipicky et  al.,  1978).  The  alternative  hypothesis 
is  that  the  local  anesthetics  may  bind  in  the  lumen  of the  Na  +  channel. 
The  binding  would  decrease  Na  +  permeability  by  occluding  the  channel 
(Strichartz,  1973; Courtney,  1975; Hille,  1977 b; Cahalan  and Almers,  1979). 
The results reported in this paper are consistent with either of these hypotheses, 
and do not distinguish between them. In either case, the receptor sites for the 
local anesthetics  must  be coupled with  gating  molecules in such  a  way that 
the  binding  of these  drugs  profoundly affect  both sodium  inactivation  and 
BTX binding. 
We have only tested two specific local anesthetics so far. Whether our results 
apply to charged and uncharged local anesthetics in general is not yet known, 
but  the  consistency  of our  results  with  the  findings  of Mrose  and  Ritchie 
TABLE  II 
COMPARISON OF EXPERIMENTAL AND PREDICTED APPARENT 
DISSOCIATION CONSTANT RATIOS* 
Dose-response curve for benzocaine  Dose-response curve for QX  572 
6.25 x  10  -5 M  QX  1.46 ￿  10  -4 M  QX  3.0 x  10  -4 M  Benz  7.0 ￿  10  -4 M  Benz 
Experimental  2.0  2,2  1.8  2.1 
One-site model  0.6  0,4  0.8  0.6 
Intermediate  1.0  1,1  1.0  1.0 
model 
Two-site model  1.9  2.4  1.6  2. / 
* Ratio of Ki for one-drug experiment to Ki in presence of second drug. 
(1978)  in  their  work with  lidocaine,  marcaine,  and  benzocaine  suggest  the 
possible generality of the two-separate-site model. 
The  finding  that  there  are  two separate  sites  for  local  anesthetics  in  the 
sodium channel  suggests the possible clinical  usefulness of obtaining a  given 
degree of channel blocking by using mixtures of two drugs--each drug binding 
to a  different receptor.  As previously indicated,  the binding of two different 
drugs at two separate sites in a channel decreases the probability that a closed 
channel will open, thus driving the equilibrium toward the closed state. Thus, 
the use of two drugs  might  reduce the required  dose, particularly  if a  large 
fraction of channels needs to be blocked. As a result, there may be a reduction 
in local anesthetic side effects. 
APPENDIX 
One Drug 
For the case in which one local anesthetic competes with BTX for a  single class of 
binding sites, the equilibrium can be described as follows: HUANG AND  EHRENSTEIN 
C-Q 





where C-B represents channels with local anesthetic B bound and the other symbols 





C+BTX  ~  C-BTX 
where C  represents unbound channels, C-BTX represents channels with BTX bound 
and C-Q represents channels with local anesthetic Qbound. The dissociation constants 





KQ =  [C-Q] 
The total concentration  of channels  is  [CT]  =  [C]  4"  [C-BTX]  +  [C-Q]. Since  the 
measured flux is proportional to the concentration of channels with BTX bound, 
Flux or  [C-BTX] =  [C]  [BTX] 
KBTX 
Substituting the value of [C] from the preceding equations, 
[BTX][CT] 
Flux  oc 
[BTXI + [Q]'~ 
KBTX  1 +  KBTX  -K-Q'Q/ 
For a given value of  [BTX] and a given preparation, the maximum  flux  corresponds 
to [Q] = 0. Therefore, 
I+ [BTX__~] 
Flux  KBTX 
[BTX]  [Q]  (1A)  Max flux  1 +  +- 
KBTX  KQ 
Eq.  1A  is  the  normalized  dose-response  curve  for  one  local  anesthetic  drug  (Q) 
competing with BTX for a single class of sites. 
Two Drugs,  One-Site Model 
For  the  case  where  two  local  anesthetics  compete with  BTX  for  a  single  class  of 
binding sites, the equilibrium can be described as follows: 
C-Q 
q 
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arc the same as described. Using reasoning similar to that employed for the one-drug 
model, the normalizcd dose-response curve for two local anesthetic drugs competing 
with BTX for a single class of sites is: 
1 +  [BTX] +  [B] 
Flux  KBTX  KB 
Max flux  1  KBTX +  KB  KQ 
+  [BTX]  [B] +  [Q]  (2A) 
Two Drugs, Two-Separate-Site Model 
Next, we consider the case in which  there are two sites at each channel;  one binds 
only charged local anesthetics and the other binds only uncharged local anesthetics. 
Binding  at  either  of these  sites  and  binding  of BTX  are  mutually  exclusive.  The 
equilibrium for this case can be described as follows: 
c-O_  +  %  KQ 
B  Q 
Q  B 
+  /~ 







C  +  BTX Ks~_vx C-BTX 
where C-B-Q represents channels  with  both local anesthetics  bound  and  the other 
symbols are the same as described. For simplicity, we have assumed that the two sites 
are independent.  Therefore, the normalized dose-response curve for this case is 
[BTX]  [B] 
1+  +- 
Flux  KBTX  KB 
-  [BTX]  .  [B]  [Q] {  [BI~"  (3A)  Max flux  1 + ~.  ~  +  ~k 1 + --,~/ 
Two Drugs, Intermediate Model 
In  this  case,  there  are  two  sites  for each  channel:  one  binds  either  charged  local 
anesthetics or uncharged local anesthetics, and the other binds only uncharged local 
anesthetics. Binding at either of these sites and binding of BTX are mutually exclusive. 
The equilibrium  for this case can be described as follows: 
KB 
C-B-B' ~  B +  C-B 
B  B 
-4-  + 
K~  KBTX 
C-B'  ~B+C+BTX  ~--  C-BTX 
+  + 
Q  Q 
C-Q-B' .v~- B +  C-Q 
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where C-B-B' represents channels with uncharged local anesthetic bound at both sites. 
The normalized  dose-response curve for Q  when a fixed amount of B is added is 
EBTXl  EB]+IBI+  IB] 
I+~+KB  KB  KBKB]  Flux 
(4A) 
Max flux  (  [BTX]  [B]+ [B]+  [B] 2  ~+  [Q](  + [B]~ 
The normalized dose-response curve for B with the addition of the fixed amount of Q 
is 
[BTX] +  [Q] 
1 +  KBTX  gq  Flux 
Max flux =  (l  +  KnTx[BTX]+[B]+[B]+KB  ~  KnKB][B]2  ~+~[Q](I+KB][B]~  (5A) 
Apparent Dissociation  Constants 
Eqs.  1A, 2A, 3A, 4A, and 5A describe the decrease in flux as the concentration  of a 
local  anesthetic  is  increased.  Since  Eqs.  1A,  2A,  3A,  and  4A  are  of the  modified 
Michaelis-Menten form, the apparent dissociation constants can be simply determined 
by writing these equations in the standard  form: 
Ki 
Relative flux ffi 
Ki +  [Q] 
The apparent  dissociation constants for Eqs.  IA, 2A, and 3A are tabulated in Table 
I. The apparent  dissociation constants for the intermediate  case with the uncharged 
drug concentration  fixed and the charged drug concentration  varied is: 
[BTX] +  2[B] + [B]2~ 
KQ  I +  KBTX  ~  KB 2 ] 
Ki -~  (6A) 
l +  IBj 
KB 
For the intermediate case with the uncharged drug concentration varied, the equation 
(Eq. 5A) is not of the Michaelis-Menten  form. 
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